A new study in the Canadian Medical Association Journal (CMAJ) reports that the number of prescriptions in Canada for cardiovascular medications has been increasing over the last ten years. There has been a 200 percent increase in costs. Overall costs of cardiovascular medications exceeded $5 billion in 2006. And statins accounted for nearly 40 percent of the expenditure. Exercising a considerable public burden, cardiovascular disease is the leading cause of premature death and disability in Canada. Cardiovascular drugs are the most frequently prescribed medications in the country, and expenditures outpace overall drug prescription increases.
The American Heart Association has pledged $50, 000 to fund the work of University of Alabama at Birmingham (UAB) biomedical engineering undergraduate students who are working to develop a computer program that teaches CPR using hand-held remote controls from the Nintendo® Wii video game console. Students James McKee, Jack Wimbish, Haisam Islam and Zach Clark began work on the project as seniors at UAB. Along with faculty advisers Greg Walcott, M.D., associate professor of medicine, and Jack Rogers, Ph.D., associate professor of biomedical engineering, the team has been developing the Wii CPR technology for the last seven months.
For years, George Forschler knew the mitral valve in his heart was failing and would eventually need repair or replacement. Concerned about the risks associated with open heart surgery the traditional way to access a mitral valve he did his best to postpone the inevitable. Forschler, a retired U.S. Air Force Brigadier General who now heads a consulting firm, kept his heart healthy by exercising at the gym and doing weekend chores on his farm near here. During a recent family trip, Forschler developed a virus which made him feel weak. The weakness quickly progressed and prevented him from doing simple things, like standing while shaving. Then, he passed out at home and was rushed by ambulance to his community hospital.
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced today that it has received orphan drug designation from the Committee for Orphan Medical Products (COMP) of the European Medicines Agency (EMEA) for LX1032, the company's oral drug candidate for managing gastrointestinal symptoms associated with carcinoid syndrome. LX1032 is designed to reduce serotonin production in patients with metastatic carcinoid tumors. Elevated levels of serotonin contribute to the gastrointestinal and possibly other symptoms experienced by these patients.
Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing
Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on innovative oncology therapies, announced results from a Phase 1 cardiac safety study of picoplatin, a new generation platinum-based chemotherapy agent and the Company's lead product candidate. The Company worked collaboratively with the U.S. Food and Drug Administration (FDA) to design this study, which is required for new chemical entities. This study evaluated the cardiac safety of picoplatin by determining its effect on the cardiac QT/QTc interval by using time-matched pharmacokinetics and electrocardiograms (ECGs). A total of 45 patients with advanced solid malignancies received 150 mg/m2 picoplatin.
Over 3, 400 South Asians have taken part in the UK's largest study into heart failure in ethnic minority populations. Researchers at the University of Birmingham in the UK have been carrying out the study, involving members of the Indian community. Patients, who are registered with GPs in the Birmingham area of the English Midlands, were screened at their local surgery, to discover how common, heart failure is among them. The project lead is Dr Paramjit Gill, GP and Clinical Reader in Primary Care Research, Primary Care Clinical Sciences at the University of Birmingham. Funded by the British Heart Foundation and the Heart of Birmingham Primary Care Teaching Trust, the Birmingham study has already helped to identify people at very high risk.